ClinicalTrials.gg
RecruitingNCT07580703Updated May 14, 2026

A Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy

A Phase 1 interventional study of [18F]Flortaucipir Injection in AD - Alzheimer's Disease and MCI, sponsored by Eli Radiopharma. Recruiting at 1 site in China. Open to participants aged 50 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Eli Radiopharma · Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Planned enrollment
17th of 22
18 · median 70
Started
2026
the only one that year
Phase 1
10 of 22
2 open now
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Eli Radiopharma

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 17th largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 1, and was the 22nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

This is a non randomized, open-label Phase I study in Chinese participants. The goal of this clinical trial is to evaluate the safety and tolerability of a radioactive imaging agent called [18F]Flortaucipir Injection, which is used during a PET scan. The study will also measure how the agent moves through the body (pharmacokinetics), where it goes (biodistribution), the amount of radiation exposure (radiation dosimetry), and how well it may help detect signs of disease (preliminary diagnostic efficacy).

03

Conditions studied

  • AD - Alzheimer's Disease
  • MCI

Browse trials for

Keywords

  • tau-PET
  • [18F]Flortaucipir
  • Phase I
  • ELI-101
  • ELI-101-001
  • AD
  • Alzheimer's disease
  • MCI
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form (ICF).
  • Male or female aged 50-85 years.
  • Education level sufficient to cooperate with neuropsychological testing and obtain reliable results.
  • Meet the following criteria related to cognitive impairment:

    1. CN: No history of cognitive impairment, Aβ-PET negative, MRI without neurodegenerative changes.
    2. MCI: Meet core criteria for AD-related MCI, Aβ-PET positive, MRI showing neurodegenerative changes.
    3. AD: Meet core criteria for probable AD dementia, Aβ-PET positive, MRI showing neurodegenerative changes.
  • Fertile individuals: No plan for reproduction, sperm/egg donation within 6 months after signing ICF and until 6 months after study drug administration; and agreement to use highly effective (including partner).

Exclusion criteria

Exclusion Criteria:

  • Pregnant (positive pregnancy test at screening or before administration) or breastfeeding women.
  • Major surgery within 1 month prior to screening, or planned surgery during the study period.
  • Known allergy to radioactive radiation, alcohol, [18F]Flortaucipir injection, or its , or other severe allergic reactions.
  • Cognitive impairment due to causes other than AD.
  • infarction or probable multi-infarct dementia.
  • Current clinically significant psychiatric illness (e.g., major depression, schizophrenia).
  • History of epilepsy or seizures (except febrile seizures in childhood).
  • Inability to tolerate PET/MRI or presence of to PET/MRI.
  • Other neurodegenerative diseases or dementias other than AD dementia.
  • Any other condition that, in the investigator's opinion, makes the subject unsuitable for the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    CN (cognitively normal)

    Drug: [18F]Flortaucipir Injection

  • Experimental
    MCI (mild cognitive impairment)

    Drug: [18F]Flortaucipir Injection

  • Experimental
    AD (Alzheimer's disease)

    Drug: [18F]Flortaucipir Injection

Interventions

  • A radioactive diagnostic agent intended for brain positron emission tomography (PET) imaging in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD), to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs).

    Also known as: ELI-101

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: 6 days post-injection

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) - Total Radioactivity and Parent Compound

    Cmax is defined as the highest observed plasma concentration of total radioactivity (measured by gamma counting) and of the unmetabolized parent \[18F\]Flortaucipir

    Time frame: Up to 360 mins

  2. Time to Reach Cmax (Tmax) - Total Radioactivity and Parent Compound

    Tmax is the time (in minutes) at which the maximum plasma concentration (Cmax) occurs, recorded as the midpoint of the sampling interval during which the maximum is observed.

    Time frame: Up to 360 mins

  3. Terminal Half-Life (t½) of Unmetabolized Parent Compound

    Time frame: Up to 360 mins

  4. Area Under the Plasma Concentration-Time Curve (AUC0-t and AUC0-∞) of Unmetabolized Parent Compound

    AUC0-t is calculated using the linear trapezoidal rule from time 0 to the last measurable concentration. AUC0-∞ is extrapolated as AUC0-t + Ct/λz, where Ct is the last quantifiable concentration and λz is the terminal elimination rate constant.

    Time frame: Up to 360 mins

  5. Percentage of Unmetabolized Parent Compound in Plasma

    Time frame: Up to 360 mins

  6. Urinary Radioactive Excretion Rate

    Rate of radioactivity excreted in urine, expressed as percentage of injected dose per hour (%ID/h). Measured by gamma counting of collected urine aliquots over specified intervals.

    Time frame: 0-60, 60-120, 120-240, 240-360 mins post-injection

  7. Cumulative Urinary Excretion of Radioactivity

    Total cumulative percentage of the injected radioactive dose recovered in urine over time. Calculated as the sum of radioactivity excreted at each collection interval.

    Time frame: Up to 360 mins post-injection

  8. Percentage of Unmetabolized Parent Compound and Metabolites in Urine

    Relative proportion of total urinary radioactivity that corresponds to the intact \[18F\]Flortaucipir and its known radioactive metabolites.

    Time frame: Up to 360 mins post-injection

  9. Organ/Tissue Radioactivity Uptake - Percent Injected Dose (%ID)

    Percentage of the injected radioactive dose (%ID) present in each target organ or tissue (e.g., brain, liver, kidneys, lungs, bone marrow, etc.) at specified imaging time points.

    Time frame: Up to 240 mins post-injection

  10. Mean Standardized Uptake Value (SUVmean) in Target Organs/Tissues

    SUVmean is defined as the mean tissue radioactivity concentration (decay-corrected) normalized by injected dose per body weight.

    Time frame: Up to 240 mins post-injection

  11. Residence Time (Source Organ Time-Integrated Activity)

    Residence time (also known as time-integrated activity coefficient) for each source organ, expressed as hours (or minutes).

    Time frame: Up to 240 mins post-injection

  12. Absorbed Dose to Target Organs/Tissues

    Absorbed dose (mGy) to each target organ/tissue (e.g., brain, liver, kidneys, urinary bladder wall, lungs, red marrow, heart wall, spleen, thyroid, etc.) per unit administered activity (mGy/MBq).

    Time frame: Up to 240 mins post-injection

  13. Effective Dose (Whole-Body)

    Time frame: Up to 240 mins post-injection

  14. Visual Read Positivity Rate - Overall and by Subject Subgroup

    Proportion of subjects with a positive PET scan based on visual assessment (blinded, independent readers) using a predefined read criterion

    Time frame: At 80 mins post-injection

  15. Standardized Uptake Value Ratio (SUVR) - Composite Region

    SUVR is calculated as the mean standardized uptake value (SUV) in a composite target region of interest

    Time frame: At 80 mins post-injection

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 8 months is below that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2026
First posted
May 12, 2026
StartActual
Apr 23, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07580703
Lead sponsor
Eli Radiopharma
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Apr 23, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
May 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion